[1]
|
Wei, W., et al. (2020) Cancer Registration in China and Its Role in Cancer Prevention and Control. The Lancet. Oncology, 21, e342-e349. https://doi.org/10.1016/S1470-2045(20)30073-5
|
[2]
|
Dumay, A., et al. (2013) Distinct Tumor Protein p53 Mutants in Breast Cancer Subgroups. International Journal of Cancer, 132, 1227-1231. https://doi.org/10.1002/ijc.27767
|
[3]
|
Silwal-Pandit, L., Langerød, A. and Børresen-Dale, A.-L. (2017) TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harbor Perspectives in Medicine, 7, a026252. https://doi.org/10.1101/cshperspect.a026252
|
[4]
|
Luo, Q., et al. (2017) Dynamics of p53: A Master Decider of Cell Fate. Genes, 8, 66.
https://doi.org/10.3390/genes8020066
|
[5]
|
Duffy, M.J., Synnott, N.C. and Crown, J. (2017) Mutant p53 as a Target for Cancer Treatment. European Journal of Cancer (Oxford, England: 1990), 83, 258-265. https://doi.org/10.1016/j.ejca.2017.06.023
|
[6]
|
Fang, L., et al. (2018) Enhanced Breast Cancer Progression by Mutant p53 Is Inhibited by the Circular RNA Circ-Ccnb1. Cell Death and Differentiation, 25, 2195-2208. https://doi.org/10.1038/s41418-018-0115-6
|
[7]
|
Silwal-Pandit, L., et al. (2014) TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20, 3569-3580. https://doi.org/10.1158/1078-0432.CCR-13-2943
|
[8]
|
Shah, S.P., et al. (2012) The Clonal and Mutational Evolution Spectrum of Primary Triple-Negative Breast Cancers. Nature, 486, 395-399. https://doi.org/10.1038/nature10933
|
[9]
|
Jiang, G., et al. (2016) Comprehensive Comparison of Molecular Portraits between Cell Lines and Tumors in Breast Cancer. BMC Genomics, 17, 525. https://doi.org/10.1186/s12864-016-2911-z
|
[10]
|
Schmid, P., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 379, 2108-2121. https://doi.org/10.1056/NEJMoa1809615
|
[11]
|
Bykov, V.J.N. and Wiman, K.G. (2014) Mutant p53 Reactivation by Small Molecules Makes Its Way to the Clinic. FEBS Letters, 588, 2622-2627. https://doi.org/10.1016/j.febslet.2014.04.017
|
[12]
|
Zhao, D., et al. (2017) Molecularly Targeted Therapies for p53-Mutant Cancers. Cellular and Molecular Life Sciences: CMLS, 74, 4171-4187. https://doi.org/10.1007/s00018-017-2575-0
|
[13]
|
Bykov, V.J.N., et al. (2002) Restoration of the Tumor Suppressor Function to Mutant p53 by a Low-Molecular-Weight Compound. Nature Medicine, 8, 282-288. https://doi.org/10.1038/nm0302-282
|
[14]
|
Liang, Y., Besch-Williford, C. and Hyder, S.M. (2009) PRIMA-1 Inhibits Growth of Breast Cancer Cells by Re-Activating Mutant p53 Protein. International Journal of Oncology, 35, 1015-1023.
https://doi.org/10.3892/ijo_00000416
|
[15]
|
Rehman, A., et al. (2005) Proteomic Identification of Heat Shock Protein 90 as a Candidate Target for p53 Mutation Reactivation by PRIMA-1 in Breast Cancer Cells. Breast Cancer Research: BCR, 7, R765-R774.
https://doi.org/10.1186/bcr1290
|
[16]
|
Bykov, V.J.N., et al. (2005) PRIMA-1(MET) Synergizes with Cisplatin to Induce Tumor Cell Apoptosis. Oncogene, 24, 3484-3491. https://doi.org/10.1038/sj.onc.1208419
|
[17]
|
Perdrix, A., et al. (2017) PRIMA-1 and PRIMA-1 (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies. Cancers, 9, 172.
https://doi.org/10.3390/cancers9120172
|
[18]
|
Tessoulin, B., et al. (2014) PRIMA-1Met Induces Myeloma Cell Death Independent of p53 by Impairing the GSH/ROS Balance. Blood, 124, 1626-1636. https://doi.org/10.1182/blood-2014-01-548800
|
[19]
|
Peng, X., et al. (2013) APR-246/PRIMA-1MET Inhibits Thioredoxin Reductase 1 and Converts the Enzyme to a Dedicated NADPH Oxidase. Cell Death & Disease, 4, e881. https://doi.org/10.1038/cddis.2013.417
|
[20]
|
Synnott, N.C., et al. (2017) Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer? International Journal of Cancer, 140, 234-246. https://doi.org/10.1002/ijc.30425
|
[21]
|
Lehmann, S., et al. (2012) Targeting p53 in Vivo: A First-in-Human Study with p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 3633-3639. https://doi.org/10.1200/JCO.2011.40.7783
|
[22]
|
Bauer, M.R., Joerger, A.C. and Fersht, A.R. (2016) 2-Sulfonylpyrimidines: Mild Alkylating Agents with Anticancer Activity toward p53-Compromised Cells. Proceedings of the National Academy of Sciences of the United States of America, 113, E5271-E5280. https://doi.org/10.1073/pnas.1610421113
|
[23]
|
Synnott, N.C., et al. (2018) Mutant p53 as a Therapeutic Target for the Treatment of Triple-Negative Breast Cancer: Preclinical Investigation with the Anti-p53 Drug, PK11007. Cancer Letters, 414, 99-106.
https://doi.org/10.1016/j.canlet.2017.09.053
|
[24]
|
Bullock, A.N., et al. (1997) Thermodynamic Stability of Wild-Type and Mutant p53 Core Domain. Proceedings of the National Academy of Sciences of the United States of America, 94, 14338-14342.
https://doi.org/10.1073/pnas.94.26.14338
|
[25]
|
Bullock, A.N., Henckel, J. and Fersht, A.R. (2000) Quantitative Analysis of Residual Folding and DNA Binding in Mutant p53 Core Domain: Definition of Mutant States for Rescue in Cancer Therapy. Oncogene, 19, 1245-1256.
https://doi.org/10.1038/sj.onc.1203434
|
[26]
|
Boeckler, F.M., et al. (2008) Targeted Rescue of a Destabilized Mutant of p53 by an in Silico Screened Drug. Proceedings of the National Academy of Sciences of the United States of America, 105, 10360-10365.
https://doi.org/10.1073/pnas.0805326105
|
[27]
|
Liu, X., et al. (2013) Small Molecule Induced Reactivation of Mutant p53 in Cancer Cells. Nucleic Acids Research, 41, 6034-6044. https://doi.org/10.1093/nar/gkt305
|
[28]
|
Olivier, M., Hollstein, M. and Hainaut, P. (2010) TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology, 2, a001008. https://doi.org/10.1101/cshperspect.a001008
|
[29]
|
Blanden, A.R., et al. (2015) Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore. Molecular Pharmacology, 87, 825-831. https://doi.org/10.1124/mol.114.097550
|
[30]
|
Yu, X., et al. (2012) Allele-Specific p53 Mutant Reactivation. Cancer Cell, 21, 614-625.
https://doi.org/10.1016/j.ccr.2012.03.042
|
[31]
|
Yu, X., et al. (2014) Small Molecule Restoration of Wild-Type Structure and Function of Mutant p53 Using a Novel Zinc-Metallochaperone Based Mechanism. Oncotarget, 5, 8879-8892. https://doi.org/10.18632/oncotarget.2432
|
[32]
|
Zaman, S., et al. (2019) Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. Molecular Cancer Therapeutics, 18, 1355-1365.
https://doi.org/10.1158/1535-7163.MCT-18-1080
|
[33]
|
Salim, K.Y., et al. (2016) COTI-2, a Novel Small Molecule That Is Active against Multiple Human Cancer Cell Lines in Vitro and in Vivo. Oncotarget, 7, 41363-41379. https://doi.org/10.18632/oncotarget.9133
|
[34]
|
Lindemann, A., et al. (2019) COTI-2, a Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-Dependent and -Independent Mechanisms. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 5650-5662. https://doi.org/10.1158/1078-0432.CCR-19-0096
|
[35]
|
Lücking, U., et al. (2020) Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. Journal of Medicinal Chemistry, 63, 7293-7325.
https://doi.org/10.1021/acs.jmedchem.0c00369
|
[36]
|
Synnott, N.C., et al. (2020) COTI-2 Reactivates Mutant p53 and Inhibits Growth of Triple-Negative Breast Cancer Cells. Breast Cancer Research and Treatment, 179, 47-56. https://doi.org/10.1007/s10549-019-05435-1
|